Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProBio: Biomarker-driven Outcome Adaptive Randomized Multi-arm Trial in Prostate Cancer
2018-002350-78Phase 3Active
- Sponsor
- Karolinska Institutet
- Start
- Jul 2018
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of abiraterone, cabazitaxel, capivasertib and darolutamide in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Progression-free survival. Started Jul 2018; status: active.
02
Drugs
abirateronecabazitaxelcapivasertibdarolutamide
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2018-002350-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002350-78.